Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
Oncolytic virus
adenovirus
immunotherapy
interleukin 7
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Cytokines have proven to be effective for cancer therapy, however whilst low-dose monotherapy with cytokines provides limited therapeutic benefit, high-dose treatment can lead to a number of adverse events. Interleukin 7 has shown promising results in clinical trials, but anti-cancer effect was limited, in part due to a low concentration of the cytokine within the tumor. We hypothesized that arming an oncolytic adenovirus with Interleukin 7, enabling high expression localized to the tumor microenvironment, would overcome systemic delivery issues and improve therapeutic efficacy. We evaluated the effects of Ad5/3-E2F-d24-hIL7 (TILT-517) on tumor growth, immune cell activation and cytokine profiles in the tumor microenvironment using three clinically relevant animal models and
Identifiants
pubmed: 35845722
doi: 10.1080/2162402X.2022.2096572
pii: 2096572
pmc: PMC9278414
doi:
Substances chimiques
Cytokines
0
Interleukin-7
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2096572Informations de copyright
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823814
Cytokine. 2019 Jun;118:115-123
pubmed: 29655570
Nat Immunol. 2013 Apr;14(4):404-12
pubmed: 23396170
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Genes Dev. 1996 Feb 15;10(4):461-77
pubmed: 8600029
Clin Cancer Res. 2010 Jan 15;16(2):727-35
pubmed: 20068111
Immunity. 2020 Jan 14;52(1):151-166.e6
pubmed: 31924474
J Biomed Sci. 2017 Jul 21;24(1):49
pubmed: 28732506
Front Immunol. 2020 Oct 06;11:577869
pubmed: 33123161
Eur J Immunol. 2011 Mar;41(3):716-25
pubmed: 21312192
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
J Exp Med. 2008 Jul 7;205(7):1701-14
pubmed: 18573906
Stem Cells. 2001;19(5):378-87
pubmed: 11553846
J Clin Oncol. 1996 Jan;14(1):7-17
pubmed: 8558223
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34452927
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
Cancer Cell. 2021 May 10;39(5):632-648.e8
pubmed: 33711273
Nat Rev Immunol. 2018 Dec;18(12):745-758
pubmed: 30242265
Mediators Inflamm. 2017;2017:9621724
pubmed: 28260841
J Immunother. 2012 Apr;35(3):283-92
pubmed: 22421946
Cold Spring Harb Protoc. 2019 Aug 1;2019(8):
pubmed: 31371467
J Immunol. 2012 Dec 15;189(12):5649-58
pubmed: 23129754
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
J Immunother. 2006 May-Jun;29(3):313-9
pubmed: 16699374
Cell Mol Immunol. 2015 Mar;12(2):213-21
pubmed: 25027969
EMBO J. 2007 Jan 24;26(2):494-504
pubmed: 17245433
Cancer Gene Ther. 2015 Jan;22(1):17-22
pubmed: 25525035
Cancer. 1998 Aug 15;83(4):797-805
pubmed: 9708948
Immunology. 1999 Nov;98(3):400-5
pubmed: 10583600
Hum Gene Ther. 2000 Jan 1;11(1):53-65
pubmed: 10646639
Nat Med. 2009 May;15(5):528-36
pubmed: 19396174
Leukemia. 1992 Nov;6(11):1177-80
pubmed: 1434800
Nat Immunol. 2019 Dec;20(12):1584-1593
pubmed: 31745336
Sci Signal. 2021 Mar 16;14(674):
pubmed: 33727336
Clin Transl Sci. 2020 Nov;13(6):1161-1169
pubmed: 32339447
Cancer Immunol Immunother. 2021 Sep;70(9):2453-2465
pubmed: 33543339
Clin Cancer Res. 2016 Jul 1;22(13):3182-91
pubmed: 26823601
Nature. 2013 Jun 27;498(7455):506-10
pubmed: 23728300
Cancer Lett. 2022 Jun 1;535:215661
pubmed: 35325845
J Virol. 2013 Nov;87(21):11884-93
pubmed: 23986597
J Clin Oncol. 1996 Oct;14(10):2666-73
pubmed: 8874325
Ann Oncol. 2018 Feb 1;29(2):523
pubmed: 28368453
Nat Protoc. 2009;4(2):206-23
pubmed: 19180090
Nat Rev Immunol. 2007 Feb;7(2):144-54
pubmed: 17259970
Blood. 2010 Apr 29;115(17):3508-19
pubmed: 20190192
Sci Transl Med. 2020 Jan 15;12(526):
pubmed: 31941828
Oncoimmunology. 2022 Jan 22;11(1):2028960
pubmed: 35083096
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31940588